

**Unravelling the nutritional threads with novel associations of cognitive functions and telomerase**

Cennet Yildiz<sup>1\*</sup>, Can Akpınaroğlu<sup>2</sup>, and Isabel Medina<sup>3</sup>

<sup>1</sup>Biothermodynamics, Technische Universität München, Freising 85354, Germany;  
cennet.yildiz@tum.de

<sup>2</sup>Department of Surgery, Yale University School of Medicine, New Haven, CT 06510, USA;  
can.akpinarolu@yale.edu

<sup>3</sup>Marine Chemistry, Instituto de Investigaciones Marinas CSIC, Vigo, Spain 36208;  
medina@iim.csic.es

**\*Correspondence:** cennet.yildiz@tum.de (C. Yildiz)

This peer-reviewed article has been accepted for publication but not yet copyedited or typeset, and so may be subject to change during the production process. The article is considered published and may be cited using its DOI.

10.1017/S0954422425100280

Nutrition Research Reviews is published by Cambridge University Press on behalf of The Nutrition Society

## Abstract

Cognitive decline is a hallmark of brain ageing. Leukocyte telomere length (LTL) has emerged as a candidate biomarker related to brain ageing and neurodegeneration; however, reported associations with cognition and brain structure vary across cohorts. Long-chain omega-3 polyunsaturated fatty acids (PUFAs), notably docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), exert anti-inflammatory and antioxidant effects that may, in some contexts, relate to slower telomere attrition. Here, we synthesize evidence on n-3 PUFAs, telomere biology, and cognitive outcomes, integrating clinical, epidemiologic, and experimental data. We emphasize biological plausibility (oxidative stress/inflammation, membrane remodeling, mitochondrial function and expression of telomerase reverse transcriptase (TERT) through PI3K/Akt/mTOR, NRF2 and epigenetic modifications) while acknowledging heterogeneous human findings and methodological considerations (assay variability, life-course timing, cognitive domains, and biomarker stratification). We outline priorities for future studies to clarify causal pathways and inform dietary strategies that support healthy cognitive ageing.

**Keywords:** n-3 PUFAs, dietary fats, neurodegenerative diseases, oxidative stress, ageing, telomere length

## Exploring n-3 PUFAs, cognitive function, and telomerase activity-dependent telomere length

Neuroscientists have recently been delving into how to prevent or mitigate the effects of ageing (see **Glossary**), particularly in cognitive decline (see **Glossary**) [1]. When it comes to cognitive decline and brain senescence, leukocyte telomere length (LTL) (see **Glossary**) proved to be a significant biomarker [2]. Along with long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs (DHA/EPA)) (see **Glossary**), consumption of vitamin A, vitamin B12, vitamin C, vitamin D, nicotinamide, folate, zinc, magnesium, and polyphenols (see **Glossary**) maintains high telomere length (TL).

This review explores recent evidence examining the associations between n-3 PUFA intake and its impact on cognitive function, focusing on LTL as a potential intermediary. Clinical and pre-clinical studies have commenced, unravelling the intricate interactions and correlations between dietary fatty acids and markers of cognitive well-being. We aim to contribute to this burgeoning field by exploring nuanced associations and shedding light on the impacts of n-3 PUFA on cognitive performance and TL.

### Telomeres and their role in ageing and health

Eukaryotic cells use highly complex processes to ensure genome stability and the proper regulation of transcription and translation [3]. Telomeres (see **Glossary**) are specialized structures at the ends of linear chromosomes in eukaryotic cells. These nucleoprotein complexes [(TTAGGG)<sub>n</sub> in mammals, including humans] have several crucial functions, primarily related to the protection and stability of the genome [4,5]. The linear configuration of chromosomes presents two significant challenges: the end-replication problem and the end-protection problem (e.g., preventing end-to-end fusions) [5]. During each replication cycle, a small fraction of telomeric DNA at the chromosome ends. In case it is unabated, chromosomal degradation and cell death are observed. Situated at the ends of the chromosomes, telomeres serve as the main solution against the end replication problem. Additionally, telomeres employ mechanisms to tackle the end protection problem [2,6]. To prevent the genome from fusing with other parts of the DNA from the hanging endpoints, telomeres behave as caps by attaching telomeric DNA via proteins. [7]. Most of the eukaryotes, but not all, engage in telomerase (see **Glossary**) to maintain TL in certain cells [7]. Telomerase includes the telomerase reverse transcriptase

(TERT) (see **Glossary**), which is the unique human telomerase element not expressed ubiquitously, and a telomerase RNA component (TERC) (see **Glossary**), enabling the template for telomere extension during de novo addition of TTAGGG repeats onto chromosome ends [8]. TERT is largely repressed in somatic tissues, with activity in germ cells and subsets of stem/activated immune cells [4]. Cancer cells synthesize telomerase to withstand extreme genomic and oxidative stress (see **Glossary**) and overcome their replication problem [9].

With each cell division, imperfect copies of the DNA at the end of each chromosome are generated, leading to the gradual shortening of telomeres. Once telomeres reach a critical length without sufficient telomerase, the replication ceases, and cells enter a state known as ‘senescence’ [10]. However, reintroducing the telomerase enzyme can reverse senescence, highlighting the critical relationship between TL and cell senescence [11].

The link between telomere shortening, inflammation, and senescence has recently been suggested as a key factor in neurodegenerative diseases. TERT could regulate oxidative stress and inflammatory responses, and slowing down telomere attrition being critical for T cell senescence and neurodegenerative diseases. Several pieces of evidence point out the modulation of TERT expression addressed by the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) [12]. NRF2 promotes the expression of telomere-associated genes, including TERT, and enhances antioxidant defenses, telomere maintenance, and protection against disrupted oxidative metabolism. Activation of NRF2 can repair DNA damage as well, thus contributing to telomere integrity.

A body of evidence indicates some determinant signaling pathways for telomerase activity targeting the regulation of TERT. Among them, mTOR, a serine/threonine protein kinase, member of the phosphatidylinositol-3 kinase (PI3K)-Akt pathway, has been involved in the pathogenesis of cognitive dysfunction and in the onset of disorders and neurodegenerative diseases [13]. It plays a key role in senescence, and the activation of the PI3K/Akt/mTOR pathway led to a decrease in telomerase activity and sped up aging, whereas inhibition of the PI3K/Akt/mTOR pathway increased telomerase activity and delayed aging [14]. The pathway impacts TERT expression through transcriptional regulation, and its downstream effects influence telomere maintenance by influencing the stability and localization of telomeric proteins like TRF1 [15].

Cellular oxidative stress and low-grade inflammation accelerate telomere attrition by increasing guanine oxidation (e.g., 8-oxoG) within telomeric repeats, inhibiting telomerase activity, and perturbing shelterin binding. These processes contribute to DNA damage responses and senescence phenotypes relevant to neurodegeneration. We therefore centralize this mechanism here and, in later sections, reference this subsection rather than restate the same material. Alternative Lengthening of Telomeres (ALT), a telomerase-independent, recombination-based pathway, is introduced here alongside telomerase to complete the telomere-maintenance landscape; while most prominent in telomerase-negative tumors and immortalized lines, ALT-like recombination events have been observed in normal mammalian somatic cells, although convincing *in vivo* evidence that ALT alone sustains telomere elongation enough to bypass replicative limits in normal tissues remains limited [16-20].

Experimental evidence indicates that telomerase contributes to tissue maintenance with potential implications for the ageing brain. In telomerase-deficient aged mice, telomerase reactivation reversed tissue degeneration [21]. Within the CNS, hippocampal telomerase activity has been linked to neurogenesis and mood-relevant behaviors [22], highlighting a mechanistic bridge between telomere maintenance and hippocampal function, a structure central to memory and cognitive ageing.

Finally, TL, telomerase activity, and epigenetic modifications are closely interrelated, and this cross-talk accompanies aging and age-related pathologies. DNA methylation, histone methylation–acetylation, and non-coding RNAs can be actors in the regulation of TERT expression in ageing and cancer, which in turn affect telomerase activity [23]. Recent research indicates that cognitive decline in Alzheimer patients is concomitant with interaction between TL and DNA methylation for triggering secondary cascades such as mitochondrial dysfunction, disrupted intercellular signaling, and chronic inflammation [24].

### **The impacts of telomere length and telomerase activity on brain functions**

The research on cognitive function over the lifespan is an emerging interest as cognitive function changes throughout the lifespan, which is essential for healthy ageing [25]. LTL affects global, regional, and subcortical grey matter volumes as well as cortical thickness in certain regions [2], which serves as markers for neurodegenerative disease (**Box 1**). TL is associated with several neurodegenerative disorders such as cognitive decline, Alzheimer's Disease (AD) (see

**Glossary**), and Parkinson's disease (PD) (see **Glossary**), Huntington's disease, as presented in Table 1 [26–29].

Genetic and non-genetic factors contribute to oxidative stress and chronic inflammation (see **Glossary**), see consolidated mechanisms for details on aging.

Across human studies, leukocyte telomere length (LTL) shows heterogeneous associations with cognitive trajectories and brain structure. Several cohorts report that shorter LTL or faster attrition relate to poorer cognitive performance or smaller brain volumes [33–45]. In contrast, other studies observe no association [46–48] or inverse patterns (longer LTL associated with worse outcomes or smaller hippocampal volume) [49–52]. These discrepancies likely reflect differences in age windows (midlife vs late-life), study design (cross-sectional vs longitudinal), LTL assay methods (monochrome qPCR, Southern blot, flow-FISH), cognitive domains tested, neurodegenerative biomarker status, and APOE genotype, sociodemographic composition (race/ethnicity, SES), sample size, and statistical adjustment. Reverse causation (preclinical disease accelerating telomere attrition) and regression-dilution bias may also contribute. Overall, evidence supports a biologically plausible link between telomere biology and brain ageing, but effect sizes are modest and context-dependent, underscoring the need for standardized LTL measurement, harmonized cognitive outcomes, and biomarker-stratified analyses.

Positive associations (longer LTL/slower attrition resulting in better outcomes):

In non-demented older adults, shorter LTL tracked with poorer cognitive-ageing indices [33]. In the Nurses' Health Study, shorter baseline LTL predicted greater 10-year cognitive decline [35]. Longer LTL is related to larger total and regional brain volumes in a population cohort [38]. Faster telomere attrition associated with medial temporal lobe atrophy and white-matter microstructural decline [42]. Short baseline LTL predicted subsequent memory decline over about 20 years, while within-person LTL change was not informative [44].

Null reports:

Community and family-based samples have also found no association between LTL and global cognition [46–48].

Inverse/context-dependent findings:

In APOE  $\epsilon 3/\epsilon 3$  carriers, longer LTL correlated with smaller hippocampal volume, suggesting genotype-specific effects[46]. In individuals along the Alzheimer's biomarker cascade, longer baseline LTL is related to faster executive decline (stage-specific effects) [38]. In MCI, telomere length was related to connectome features and showed a negative association with executive function after covariate control [49].

The neurodegenerative disorders occur due to cell senescence canonically triggered by LTL shortening [53]. The cell senescence induces an imbalance in energy metabolism[54]. Alterations in mitochondrial structure or mitochondrial DNA led to mitochondrial respiration dysfunction, which is the process that leads cells to generate energy in the form of ATP. Energy demands in the brain are notably higher than in other organs due to its high metabolic activity. Impaired mitochondrial respiration can decrease ATP production in neurons and astrocytes, influencing various cellular processes, including neurotransmitter release, synaptic function, and overall brain function. Dysfunctional mitochondria and the shorter LTL, in turn, induce cellular senescence, an irreversible cell-cycle arrest linked to age-dependent physiopathology and phenotypic alterations [55].

Microglia play vital roles in maintaining brain homeostasis by responding to molecular signals, such as ATP, and regulating synaptic activity by releasing immune transmitters like cytokines and chemokines. Moreover, microglia interact with neural circuits and impact cognitive processes, including learning and memory. Microglia also regulate adult neurogenesis and influence neurogenesis throughout the lifespan [59]. The research showed a positive correlation between microglia number and telomerase activity-dependent TL. Dysregulation in telomerase activity-dependent TL causes a reduction in the number of microglia [29]. Reports in injury models link microglial activation/state to telomerase/TL metrics; causal direction in humans remains unclear [57].

Neurons are terminally differentiated cells that do not undergo mitosis and are regarded as post-mitotic cells [58]. Due to their non-replicative nature, the neurons must be maintained and aided. Although at first glance, telomere shortening, a direct result of ageing, should not be an issue for a non-dividing cell, it turns out that despite their terminal differentiation, longer telomeres and healthy maintenance of telomeres are extremely important for the health of brain cells [59].

Although telomerase is mainly known as a telomere-maintaining enzyme (its canonical function), TERT has suggested telomere maintenance-independent functions, named non-canonical functions, such as DNA repair, apoptosis regulation, and modulation of signaling pathways [60]. TERT protects neurons against apoptosis by contributing to them becoming more resistant to programmed cell death. TERT affects brain metabolism by regulating cellular redox homeostasis and abating oxidative stress. It plays a crucial role in protecting mitochondria against reactive oxygen species (ROS) (see **Glossary**)-induced damage and improves mitochondrial function, strengthening mitochondrial membrane potential and decreasing mitochondrial ROS production [61]. Wan et al. (2021) [62] suggested that increased TERT activation improved motor functions such as gait and motor coordination in a transgenic mouse model for PD. TERT also improved the markers of autophagy and degraded toxic alpha-synuclein, which is a protein characterized by PD pathology.

### **Studies on the relationship between telomere length, n-3 PUFA, and cognitive performance**

PUFAs are also known to be indispensable for the well-being of the brain by constituting 35% of the brain lipids [63]. Docosahexaenoic acid (DHA) (see **Glossary**) has been particularly effective in supporting the brain against the onset of dementia and unhealthy brain ageing in completed clinical trials [64–67]. Indeed, supplementation with DHA seems to have protective effects against brain ageing and cognitive decline [68]. Additionally, supplementation with n-3 docosapentaenoic acid (DPA) has been associated with slower cognitive decline and AD as well [69]. Interestingly, the variation in TL, irrespective of chronological age, suggests that it is a modifiable factor that is regulated and affected by other factors like DNA damage, cell division, ageing, oxidative stress, and inflammation. As such, specific dietary constituents may be potential tools for preserving TL throughout life.

Anti-inflammatory and antioxidant-rich dietary patterns, such as Mediterranean, DASH, and MIND, associate with lower systemic inflammation and oxidative stress and have been linked to slower cognitive decline and healthier brain structure in multiple cohorts. Because oxidative stress and inflammation accelerate telomere shortening, these diets provide a biologically plausible pathway whereby n-3 PUFAs and broader dietary patterns may preserve telomere integrity and, in turn, support healthy cognitive ageing. Mechanistically, reduced NF-κB



signaling, improved redox balance (e.g., via Nrf2-regulated responses), and membrane remodeling may converge on slower telomere attrition and improved neurocognitive outcomes.

One of the most relevant observations of brain ageing research pointed out that age-related cognitive decline is not only due to neuronal loss, as previously thought. Oxidative imbalance and chronic inflammation are key issues in this deterioration. Both conditions can contribute to the development of neurodegenerative diseases (see **Glossary**) or be a result of neuronal degeneration. Moreover, these two pathological hallmarks are linked, and it is known that oxidative stress can affect the inflammatory response. TL is affected by both oxidative stress and inflammation. In fact, oxidative stress highly addresses telomere shortening/dysfunction [70]. Nutritional interventions with fish oils enriched in n-3 PUFA-rich interventions have shown ameliorating effects on the triad of inflammation, oxidative stress, and immune cell ageing, representing important mechanisms underlying ageing. Then, a higher intake of n-3 PUFAs can play a role in telomere maintenance and influence overall health and longevity [71]. n-3 PUFA may protect chromosomal integrity and attenuate DNA oxidative damage by anti-inflammatory and pro-resolving actions, and modulation of redox pathways through the contribution of nuclear factor erythroid 2 (NF-E2)-related factor-2 (Nrf2) (see **Glossary**) [72]. Nrf2 plays a critical role in the antioxidant response (see **Glossary**) and activates the expression of cytoprotective proteins and detoxification enzymes. Anti-inflammatory properties of n-3 PUFAs are associated with inhibition of proinflammatory transcription factors, leucocyte chemotaxis, and oxylipin production [73]. Their enzymatic anti-inflammatory metabolites, like eicosanoids and docosanoids, can influence low-grade systemic inflammatory conditions associated with endothelial dysfunction, with significant changes in the immune system. A close interaction exists among PUFAs and their metabolites, telomere length, and ageing process.

The relationship between TL, n-3 PUFA, and cognitive performance has garnered significant scientific interest, revealing intricate connections between diet, cellular ageing, and mental health. Cassidy et al. (2010) [74] suggested that body composition and dietary factors affect leukocyte TL in the population of middle- and older age women. Numerous studies have highlighted how specific dietary components can influence telomere attrition, with particular attention to the benefits of monounsaturated fatty acids (MUFA) (see **Glossary**) and PUFA, especially within dietary patterns like the Mediterranean diet, known for its high content of these

nutrients [75–77]. Such diets have been associated with slower telomere shortening and, consequently, decelerated ageing processes. The results of a prospective cohort study on 608 ambulatory outpatients by Farzareh et al. (2010) [78] indicated that higher n-3 PUFA levels were positively correlated with a smaller decrease in TL over 5-year period. Even after adjusting for various confounders, the association between higher n-3 PUFAs may play a role in showing the ageing process at the cellular level.

A recent study utilizing Mendelian-randomization analysis aimed to investigate how MUFAs, PUFAs, and saturated fatty acids (SFAs) (see **Glossary**) affect ageing by comparing proxy indicators of the frailty index (FI), facial ageing (FA), and TL [51]. While MUFAs and PUFAs were found to be halting the progress of ageing, SFAs were detected to hasten the process. No significant correlations were detected among FI and FA, and MUFAs, PUFAs and SFAs. The main indicator and the molecular biomarker for the effect of ageing was TL, and while MUFAs and PUFAs were correlated with higher TL, SFAs had an inverse correlation.

Reduction in TL with increasing age is a common phenomenon in all somatic cells. However, recent studies have suggested that TL can also be enhanced in bodily cells [79,80]. Such a reverse attrition difference in TL was attributed to changes in oxidative stress. Thus, supplementation with n-3 PUFA provoked significant changes in TL, which were associated with effects on oxidative stress, inflammation, and immune cell ageing, which were improved with dietary modifications [81]. Healthy lifestyle and anti-inflammatory diets may reduce oxidative stress and thus indirectly support telomere maintenance via canonical pathways; effects on ALT in normal tissues are unproven [82]. A proposed mode of working mechanism of ALT is a controlled homology-directed repair mechanism created in a controlled manner. Another suggested model explaining ALT is the formation of Holliday junctions at the T-loop structures in mammalian DNA, where the loop is formed by the 3' overhang fusing to its preceding strand [71].

A meta-analysis study by Ali et al. (2022) [83] put forward that n-3 PUFA supplementation may contribute to telomere maintenance and, by extension, influence ageing and disease prevention despite the limited number of clinical studies. The researchers suggested that the protective effects of n-3 PUFAs on telomeres may be attributed to their anti-inflammatory and antioxidant properties. These fatty acids modulate inflammatory pathways and enhance antioxidant defenses,

potentially through the activation of Nrf2 and the regulation of the expression of antioxidant properties. The convergence of findings from studies on TL, n-3 PUFA, and cognitive performance suggests a synergistic relationship (see **Box 2**). The anti-inflammatory and antioxidative effects of n-3 PUFAs may contribute to the preservation of TL, which in turn could mitigate cognitive decline. A study by O’Callaghan et al. (2014) [84] revealed that older adults with MCI who received eicosapentaenoic acid (EPA) (see **Glossary**) and DHA supplements had reduced telomere shortening compared to those who took n-6 linoleic acids supplements. Wu et al. (2023) [85] found that DHA supplementation significantly attenuated telomere attrition in blood leukocytes and various tissues, suggesting a protective effect against telomere shortening. The follow-up study with mice supplemented with DHA led to reduced ageing phenotypes, such as lower  $\beta$ galactosidase activity, indicative of reduced cellular senescence. DHA intervention reduced telomere attrition-induced DNA damage as indicated by lower  $\gamma$  – H2AX levels and enhanced recruitment of PARP1 poly(ADP-ribose) polymerase 1 (PARP1), a key protein in DNA repair. DHA suppressed the *NF- $\kappa$ B/NLRP3/caspase-1* pathways, suggesting anti-inflammatory effects. DHA also improved mitochondrial function, reduced ROS accumulation, and decreased markers of oxidative stress by improving mitochondrial homeostasis and thus reduced mitochondrial damage. All these effects are crucial to maintaining healthy ageing and cognitive functions (see **Glossary**). Barden et al. (2016) [86] also stated that the potential impact of n-3 acids on the increase of telomere length, adjusted for neutrophil count, may be associated with diminished oxidative stress and enhanced elimination of neutrophils with shorter telomeres from the circulation. All these animal and human studies reveal that there is an association between n-3 PUFAs, TL, and cognitive outcomes.

### **Discussions of findings and potential mechanisms**

TL is a critically important parameter in all cells for optimal functioning, even in terminally differentiated post-mitotic neuronal cells, as demonstrated in a recent study comparing astrocytes and motor neurons generated with different TLs [59]. Cells with shorter TL showed elevated inflammation, higher cellular senescence, and increased DNA damage. Combined with highly substantial evidence accumulating in the last decade that non-canonical functions of TERT are associated to preserving the genome against sources of DNA damage, including oxidative stress,

and the fact that neither the correlation of telomeres nor TERT is properly elucidated, telomeres and TERT emerge as highly promising research for nutrition, ageing, and therapeutic medicine.

Another promising research related to non-canonical cellular TERT mechanisms is the capacity for MUFAs and PUFAs to mitigate telomere attrition. The beneficial effects of different diets on maintaining TL have already been discovered [75]. However, pinpointing the exact sources of nutrients leading to this effect and the exact molecular mechanisms underlying it are not well elucidated.

Interestingly, *n*-3 PUFAs supplementation has been associated with pathways affecting TERT expression and telomerase activity. The mTOR pathway is known to be activated by multiple factors, including insulin and nutrients. Both in vitro and in vivo studies have reported mTOR as an omega-3 target in different pathological conditions [87]. In fact, *n*-3 PUFAs inhibit mTOR through different mechanisms, including interference with the PI3K/Akt pathway. The regulatory role of the mTOR signaling pathway has been closely associated to the prevention of major neurological diseases, considering its ability to modulate autophagy, protein synthesis in neurons, and the maintenance of synaptic plasticity underlying memory formation. Furthermore, the inhibition of mTOR could exert a protective effect on the brain against inflammation.

*n*-3 PUFAs are suggested to possess the ability to restore NRF2 function, maintain a proper redox balance, and preserve telomere length during aging. In particular, oxidized lipid metabolites as eicosanoids and docosahexanoids coming from the enzymatic action of cyclooxygenases, lipoxygenases, and cytochrome P450 over EPA and DHA, are suggested as effective NRF2 inducers [88]. These metabolites are lipid mediator triggers for the NRF2 pathway by quickly reacting with specific cysteine residues of KEAP1, which is the endogenous inhibitor of NRF2.

Among mechanisms to control TERT gene regulation, some dietary compounds, such as *n*-3 PUFAs, can alter normal epigenetic states, influencing gene expression, development, metabolism, and phenotype. Diet components can also modulate epigenetic modifications, resulting in reverse abnormal gene activation or silencing. Supplementation with *n*-3 PUFA addressed methylation of genes and overexpressed several key pathways associated with the onset of cognitive decline as those related to inflammatory, immune response, and lipid metabolism [89]. DHA and EPA are indeed suggested as DNA methylation modulators due to

their ability to correct aberrant acetylation and methylation profiles and restore normal patterns. This effect of repair is a key epigenetic mechanism that regulates gene expression in the brain.

### **Gaps in the literature and areas for future research**

The telomeres need to withstand oxidative stress and other possible DNA damage causes, even when the chromosome is not being replicated. Mechanistic pathways are summarized in the consolidated mechanisms subsection [95, 96]. Considering the recent findings of how TERT is also somehow related to neuronal health by non-canonical means, the underlying mechanisms need to be fully resolved [60]. A recent similar experiment was designed by creating neurons with different TLs from induced pluripotent stem cells (iPSCs), and indeed, a correlation between short TL and neurodegenerative diseases was found [59]. However, the mechanism that can explain this correlation is still not clear.

Among many nutrients, MUFAs and PUFAs help protect the brain against ageing. A significant amount of the molecular constitution of brain lipids is PUFAs; however, the molecular process of how the consumption of PUFAs protects against brain ageing is not well explained in relation to the protective effect on TL. While fish oil, especially DHA and EPA, was observed to protect the cells against oxidative stress in some studies, long-term consumption of fish oil was observed to increase oxidative stress and even promote ageing [92,93]. This counter relation of PUFAs promoting oxidative stress and ageing on their long-term intake illustrates how the exact mechanism of PUFAs, ageing, and TL still needs to be well studied, with research focusing on lipid metabolism.

### **Concluding Remarks**

Evidence linking n-3 PUFAs, epigenetic/signaling modulation, and broader anti-inflammatory and antioxidant patterns to telomere biology and cognitive ageing is biologically plausible and supported in several cohorts, yet findings are heterogeneous across designs, age windows, assays, and populations. Effect sizes appear modest and may depend on neurodegenerative biomarker status, APOE genotype, and sociodemographic context; thus, claims of uniform benefit are not warranted.

To clarify causality and resolve discrepancies, future work should (i) standardize LTL measurement and reporting across platforms (qPCR, Southern blot, flow-FISH), (ii) harmonize cognitive outcomes and integrate multimodal MRI, (iii) adopt longitudinal, life-course designs with pre-specified analyses, (iv) stratify by biomarkers (e.g., amyloid/tau) and APOE, (v) ensure diverse sampling with SES/race adjustments, and (vi) complement observational data with MR and rigorously powered dietary or supplementation trials. These steps will determine when, and for whom, dietary strategies may help preserve telomere integrity and support brain health.

**Acknowledgements.** We confirm that Grammarly was used for language editing only.

**Financial support.** This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

**Declaration of interests.** The authors declare that they have no conflicts of interest.

**Author contributions.** All authors contributed equally to the manuscript, as outlined below:

CY: conceptualization, study design, original draft preparation, review and editing, visualization

CA: study design, original draft preparation, review, and editing

IM: study design, original draft preparation, supervision, review, and editing

## References

1. Fisher, G.G. *et al.* (2017) Cognitive functioning, aging, and work: A review and recommendations for research and practice. *J Occup Health Psychol* 22, 314–336
2. Topiwala, A. *et al.* (2023) Telomere length and brain imaging phenotypes in UK Biobank. *PLoS One* 18
3. Valeeva, L.R. *et al.* (2023) Telomere biology and ribosome biogenesis: structural and functional interconnections *Biochemistry and Cell Biology*, 101 Canadian Science Publishing, 394–409
4. Donate, L.E. and Blasco, M.A. (2011) Telomeres in cancer and ageing *Philosophical Transactions of the Royal Society B: Biological Sciences*, 366 Royal Society, 76–84
5. Smith, E.M. *et al.* (2020) Structural biology of telomeres and telomerase *Cellular and Molecular Life Sciences*, 77 Springer, 61–79
6. Li, Q. *et al.* (2019) Altered short chain fatty acid profiles induced by dietary fiber intervention regulate AMPK levels and intestinal homeostasis. *Food Funct* 10, 7174–7187
7. Dey, A. and Chakrabarti, K. (2018) Current perspectives of telomerase structure and function in eukaryotes with emerging views on telomerase in human parasites *International Journal of Molecular Sciences*, 19 MDPI AG
8. Lu, J. *et al.* (2013) Deletion of the major peroxiredoxin Tsa1 alters telomere length homeostasis. *Aging Cell* 12, 635–644
9. Gunes, C. *et al.* (2018) Telomeres in cancer *Differentiation*, 99 Elsevier Ltd, 41–50
10. Wattis, J.A.D. *et al.* (2020) Mathematical modelling of telomere length dynamics. *J Math Biol* 80, 1039–1076
11. Zhu, H. and van der Harst, P. (2014) Telomere Biology in Senescence and Aging. In *Inflammation, Advancing Age and Nutrition*, pp. 71–84, Elsevier
12. Medoro, A. *et al.* (2024) NRF2 signaling pathway and telomere length in aging and age-related diseases. *Mol Cell Biochem* 479, 2597–2613
13. Wong, M. (2013) Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases. *Biomed J* 36, 40
14. Tan, P. *et al.* (2016) The PI3K/Akt/mTOR pathway regulates the replicative senescence of human VSMCs. *Mol Cell Biochem* 422, 1–10

15. Liu, M. *et al.* (2024) The regulations of telomerase reverse transcriptase (TERT) in cancer. *Cell Death Dis* 15, 90
16. Neumann, A.A. *et al.* (2013) Alternative lengthening of telomeres in normal mammalian somatic cells. *Genes Dev* 27, 18–23
17. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. *Nat Rev Genet.* 2010 May;11(5):319-30. doi: 10.1038/nrg2763. Epub 2010 Mar 30. PMID: 20351727. (it is from the same author but a better article )
18. Coluzzi, E. *et al.* (2014) Oxidative stress induces persistent telomeric DNA damage responsible for nuclear morphology change in mammalian cells. *PLoS One* 9
19. Aubert, G. (2014) Telomere dynamics and aging. In *Progress in Molecular Biology and Translational Science* 125, pp. 89–111, Elsevier B.V.
20. Blasco, M.A. (2007) Telomere length, stem cells and aging. *Nature Chemical Biology*, 3Nature Publishing Group, 640–649.
21. Jaskelioff, M. *et al.* (2011) Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. *Nature* 469, 102–106
22. Zhou, Q.-G. *et al.* (2011) Hippocampal Telomerase Is Involved in the Modulation of Depressive Behaviors. *The Journal of Neuroscience* 31, 12258–12269
23. Wang, K. *et al.* (2022) Epigenetic regulation of aging: implications for interventions of aging and diseases. *Signal Transduct Target Ther* 7, 374
24. Andrews, S.J. *et al.* (2025) Integrative effects of Telomere Length, Epigenetic Age, and Mitochondrial DNA abundance in Alzheimer’s Disease
25. Fisher, G.G. *et al.* (2019) Theories of Cognitive Aging and Work. In *Work Across the Lifespan*, pp. 17–45, Elsevier
26. Sindi, S. *et al.* (2021) Telomere length change in a multidomain lifestyle intervention to prevent cognitive decline: A randomized clinical trial. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences* 76, 491–498
27. Wikgren, M. *et al.* (2014) Shorter telomere length is linked to brain atrophy and white matter hyperintensities. *Age Ageing* 43, 212–217
28. Cao, Z. *et al.* (2023) Leucocyte telomere length, brain volume and risk of dementia: A prospective cohort study. *Gen Psychiatr* 36




29. Khan, A.M. *et al.* (2015) Telomere dysfunction reduces microglial numbers without fully inducing an aging phenotype. *Neurobiol Aging* 36, 2164–2175
30. Bernardes de Jesus, B. *et al.* (2012) Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. *EMBO Mol Med* 4, 691–704
31. Roberts, R.O. *et al.* (2014) Short and long telomeres increase risk of amnesic mild cognitive impairment. *Mech Ageing Dev* 141–142, 64–69
32. Scarabino, D. *et al.* (2019) Leukocyte telomere shortening in Huntington's disease. *J Neurol Sci* 396, 25–29
33. Harris, S.E. *et al.* (2006) The association between telomere length, physical health, cognitive ageing, and mortality in non-demented older people. *Neurosci Lett* 406, 260–264
34. Valdes, A.M. *et al.* (2010) Leukocyte telomere length is associated with cognitive performance in healthy women. *Neurobiol Aging* 31, 986–992
35. Devore, E.E. *et al.* (2011) Relative telomere length and cognitive decline in the Nurses' Health Study. *Neurosci Lett* 492, 15–18
36. Yaffe, K. *et al.* (2011) Telomere length and cognitive function in community-dwelling elders: Findings from the Health ABC Study. *Neurobiol Aging* 32, 2055–2060
37. Ma, S.L. *et al.* (2013) Telomere length and cognitive function in southern Chinese community-dwelling male elders. *Age Ageing* 42, 450–455
38. King, K.S. *et al.* (2014) Effect of Leukocyte Telomere Length on Total and Regional Brain Volumes in a Large Population-Based Cohort. *JAMA Neurol* 71, 1247
39. Cohen-Manheim, I. *et al.* (2016) Increased attrition of leukocyte telomere length in young adults is associated with poorer cognitive function in midlife. *Eur J Epidemiol* 31, 147–157
40. Hägg, S. *et al.* (2017) Short telomere length is associated with impaired cognitive performance in European ancestry cohorts. *Transl Psychiatry* 7, e1100–e1100
41. Scarabino, D. *et al.* (2017) Leukocyte telomere length in mild cognitive impairment and Alzheimer's disease patients. *Exp Gerontol* 98, 143–147
42. Staffaroni, A.M. *et al.* (2018) Telomere attrition is associated with declines in medial temporal lobe volume and white matter microstructure in functionally independent older adults. *Neurobiol Aging* 69, 68–75

43. Leibel, D.K. *et al.* (2020) Telomere length and cognitive function: Differential patterns across sociodemographic groups. *Neuropsychology* 34, 186–198
44. Pudas, S. *et al.* (2021) Short Leukocyte Telomeres, But Not Telomere Attrition Rates, Predict Memory Decline in the 20-Year Longitudinal Betula Study. *The Journals of Gerontology: Series A* 76, 955–963
45. Mahady, L.J. *et al.* (2021) Telomeric alterations in the default mode network during the progression of Alzheimer's disease: Selective vulnerability of the precuneus. *Neuropathol Appl Neurobiol* 47, 428–440
46. Insel, K.C. *et al.* (2012) Biomarkers for Cognitive Aging Part I. *Biol Res Nurs* 14, 124–132
47. Ashrafi, A. *et al.* (2020) Leukocyte telomere length is unrelated to cognitive performance among non-demented and demented persons: An examination of long life family study participants. *Journal of the International Neuropsychological Society* 26, 906–917
48. Kaja, R. *et al.* (2019) Association between telomere length and cognitive ability in a community-based sample. *Neurobiol Aging* 75, 51–5
- Mahoney, E.R. *et al.* (2019) Telomere length associations with cognition depend on Alzheimer's disease biomarkers. *Alzheimer's & Dementia: Translational Research & Clinical Interventions* 5, 883–890
49. Yu, J. *et al.* (2020) The functional and structural connectomes of telomere length and their association with cognition in mild cognitive impairment. *Cortex* 132, 29–40
50. Wikgren, M. *et al.* (2012) Longer Leukocyte Telomere Length Is Associated with Smaller Hippocampal Volume among Non-Demented APOE  $\epsilon 3/\epsilon 3$  Subjects. *PLoS One* 7, e34292
51. Mather, K.A. *et al.* (2010) Cognitive performance and leukocyte telomere length in two narrow age-range cohorts: a population study. *BMC Geriatr* 10, 62
52. Mahoney, E.R. *et al.* (2019) Telomere length associations with cognition depend on Alzheimer's disease biomarkers. *Alzheimer's & Dementia: Translational Research & Clinical Interventions* 5, 883–890
53. Hayflick, L. and Moorhead, P.S. (1961) The serial cultivation of human diploid cell strains. *Exp Cell Res* 25, 585–621
54. Tan, F.C.C. *et al.* (2014) Are there roles for brain cell senescence in aging and neurodegenerative disorders? *Biogerontology*, 15, 643–660

55. Asghar, M. *et al.* (2021) Mitochondrial biogenesis, telomere length and cellular senescence in Parkinson's disease and Lewy body dementia.
56. Augusto-Oliveira, M. *et al.* (2019) What do microglia really do in healthy adult brain? *Cells* 8, 1293
57. Flanary, B.E. and Streit, W.J. (2005) Effects of axotomy on telomere length, telomerase activity, and protein in activated microglia. *J Neurosci Res* 82, 160–171
58. Aranda-Anzaldo, A. (2012) The post-mitotic state in neurons correlates with a stable nuclear higher-order structure. *Commun Integr Biol* 5, 134–139
59. Harley, J. *et al.* (2024) Telomere shortening induces aging-associated phenotypes in hiPSC-derived neurons and astrocytes. *Biogerontology* 25, 341–360
60. Saretzki, G. and Wan, T. (2021) Telomerase in brain: The new kid on the block and its role in neurodegenerative diseases. *Biomedicines* 9, 490
61. Rosen, J. *et al.* (2020) Non-canonical functions of telomerase reverse transcriptase – Impact on redox homeostasis. *Redox Biology*, 34, 101543
62. Wan, T. *et al.* (2021) Increased telomerase improves motor function and alpha-synuclein pathology in a transgenic mouse model of Parkinson's disease associated with enhanced autophagy. *Prog Neurobiol* 199, 101953
63. Zeman, M. *et al.* (2012) *N-3 polyunsaturated fatty acids in psychiatric diseases: Mechanisms and clinical data*, 33(8), 736-48.
64. Kotani, S. *et al.* (2006) Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. *Neurosci Res* 56, 159–164
65. Freund-Levi, Y. *et al.* (2006)  $\omega$ -3 fatty acid treatment in 174 patients with mild to moderate Alzheimer's Disease: OmegAD study. *Arch Neurol* 63, 1402
66. van de Rest, O. *et al.* (2008) Effect of fish oil on cognitive performance in older subjects. *Neurology* 71, 430–438
67. Shinto, L. *et al.* (2013) A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's Disease. *Journal of Alzheimer's Disease* 38, 111–120
68. Cole, G.M. *et al.* (2010) Dietary fatty acids and the aging brain. *Nutr Rev* 68, S102–S111
69. de Oliveira Otto, M.C. *et al.* (2023) Circulating Omega-3 and Omega-6 fatty acids, cognitive decline, and dementia in older adults. *Journal of Alzheimer's Disease* 95, 965–979


70. Blackburn, N.B. *et al.* (2015) A retrospective examination of mean relative telomere length in the Tasmanian Familial Hematological Malignancies Study. *Oncol Rep* 33, 25–3
71. Kiecolt-Glaser, J.K. *et al.* (2013) Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: A randomized controlled trial. *Brain Behav Immun* 28, 16–24
72. Golpour, P. *et al.* (2020) Improvement of NRF2 gene expression and antioxidant status in patients with type 2 diabetes mellitus after supplementation with omega-3 polyunsaturated fatty acids: A double-blind randomised placebo-controlled clinical trial. *Diabetes Res Clin Pract* 162, 108120
73. Misheva, M. *et al.* (2022) Oxylin metabolism is controlled by mitochondrial  $\beta$ -oxidation during bacterial inflammation. *Nat Commun* 13, 139
74. Cassidy, A. *et al.* (2010) Associations between diet, lifestyle factors, and telomere length in women. *American Journal of Clinical Nutrition* 91, 1273–1280
75. Öngel, M.E. *et al.* (2021) Why women may live longer than men do? A telomere-length regulated and diet-based entropic assessment. *Clinical Nutrition* 40
76. Galiè, S. *et al.* (2020) Impact of Nutrition on Telomere Health: Systematic Review of Observational Cohort Studies and Randomized Clinical Trials. *Advances in Nutrition*, , 576–601
77. Marti, A. *et al.* (2023) Effect of a 3-year lifestyle intervention on telomere length in participants from PREDIMED-Plus: A randomized trial. *Clinical Nutrition* 42, 1581–1587
78. Farzaneh-Far, R. *et al.* (2010) Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. *JAMA* 303, 250–257
79. Shlush, L.I. *et al.* (2011) Telomere elongation followed by telomere length reduction, in leukocytes from divers exposed to intense oxidative stress - Implications for tissue and organismal aging. *Mech Ageing Dev* 132, 123–130
80. Svenson, U. *et al.* (2011) Blood cell telomere length is a dynamic feature. *PLoS One* 6, e21485
81. Kiecolt-Glaser, J.K. *et al.* (2013) Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: A randomized controlled trial. *Brain Behav Immun* 28, 16–24
82. Ng, G.Y.-Q. *et al.* (2022) Effects of dietary interventions on telomere dynamics. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis* 876–877, 503472

83. Ali, S. *et al.* (2022) Effect of omega-3 fatty acids on the telomere length: A mini meta-analysis of clinical trials. *Biomol Concepts* 13, 25–33
84. O’Callaghan, N. *et al.* (2014) Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with  $\omega$ -3 fatty acid supplementation: A randomized controlled pilot study. *Nutrition* 30, 489–491
85. Wu, S. *et al.* (2023) Lifelong docosahexaenoic acid intervention ameliorates aging in the telomere-DNA-mitochondria axis in telomerase-deficient mice. *J Nutr Biochem* 112, 109202
86. Barden, A. *et al.* (2016) n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease. *Nutrients* 8, 175
87. Shirooie, S. *et al.* (2018) Targeting mTORs by omega-3 fatty acids: A possible novel therapeutic strategy for neurodegeneration? *Pharmacol Res* 135, 37–48
88. Davinelli, S. *et al.* (2022) Targeting NRF2–KEAP1 axis by Omega-3 fatty acids and their derivatives: Emerging opportunities against aging and diseases. *Free Radic Biol Med* 193, 736–750
89. González-Becerra, K. *et al.* (2019) Fatty acids, epigenetic mechanisms and chronic diseases: a systematic review. *Lipids Health Dis* 18, 178
90. Saretzki, G. (2022) Telomerase and neurons: an unusual relationship. *Neural Regen Res* 17, 2364
91. Gampawar, P. *et al.* (2022) Telomere length and brain aging: A systematic review and meta-analysis. *Aging Research Reviews*, 80, 101679
92. Tsuduki, T. *et al.* (2011) Long-term intake of fish oil increases oxidative stress and decreases lifespan in senescence-accelerated mice. *Nutrition* 27, 334–337
93. Lima Rocha, J.É. *et al.* (2022) Effects of Fish Oil Supplementation on Oxidative Stress Biomarkers and Liver Damage in Hypercholesterolemic Rats. *Nutrients* 14, 426



**Figure 1.** The effects of genetics, environmental factors, and lifespan on telomerase activity and dependent telomere length. Genetic factors such as gender and hormones, environmental factors such as infections and UVA, UVB, infrared radiation, and lifestyle factors such as dietary habits and sleeping trigger reactive oxygen species and inflammation, which cause telomere shortening by decreasing telomerase activity [16].





**Figure 2.** Genetic and non-genetic factors impact telomere length, biological ageing, and cognitive decline. Genetic and non-genetic factors may cause oxidative stress and chronic inflammation, which cause telomere shortening [16]. The shortening of telomeres accelerates biological ageing, shown as a gradient from longer telomeres (healthier) to shorter telomeres (aged) [24]. The diagram further connects telomere shortening to cognitive decline and the risk of neurodegenerative diseases (NDD), including Alzheimer's Disease (AD). This is depicted by a progression of brain images from a healthy brain to severe AD, showing a reduction in global brain volume [28].

**Table 1.** Summary of studies investigating telomere length and cognitive health

Authors	Study Type	Model Organism and Sample Size	Method	Results
Sindi et al., 2021 [26]	RCT*	Human n=756 (377 intervention, 379 control)	Participants aged 60–77 were assigned to a multidomain lifestyle intervention or control group. Cognitive change was measured using the Neuropsychological Test Battery z-score. Relative leukocyte telomere length (LTL) was measured via quantitative real-time polymerase chain reaction (qPCR).	Interaction analyses revealed better LTL maintenance among specific subgroups. LTL maintenance correlated with more pronounced cognitive intervention benefits, suggesting the potential role of telomere length (TL) in cognitive ageing and dementia prevention.
Wikgren et al., 2014 [27]	OCS*	Human n= 102 (51 female, 51 male)	Non-demented individuals aged 64–75 were assessed for leukocyte TL using qPCR. Brain atrophy and white matter hyperintensities (WMHs) were evaluated via magnetic resonance imaging (MRI).	TL was associated with subcortical WMHs than periventricular WMHs, suggesting a link between TL and vascular changes. TL may reflect cumulative exposure to age-related processes affecting white matter integrity.
Cao et al., 2023 [28]	PCS*	Human peripheral blood samples n=439,961	LTL was measured using qPCR in participants from the UK Biobank. Electronic health records tracked dementia cases, and MRI assessed brain structure in a subset.	Shorter LTL was associated with an increased risk of dementia and Alzheimer's disease (AD), as well as smaller total brain volume and reduced volumes of specific brain regions. LTL may serve as a predictive biomarker for assessing brain health.
Bernardes de Jesus et al., 2012 [30]	Experimental study	Mouse n= 89	Mice were injected with adeno-associated vectors expressing different genes. Various assays assessed treatment effects, including telomere Q-FISH analysis, bone density measurements, and neuromuscular coordination tests.	Telomerase gene therapy extended the health span and lifespan in adult and old mice without increasing cancer risk. Treatment led to rejuvenating effects, including delayed osteoporosis and improved metabolic function. The therapy increased TL and decreased the abundance of short telomeres, indicating potential long-term benefits.
Roberts et al., 2014 [31]	OChS*	Human n= 437 (with MCI*) n= 691 (control)	TL was measured using qPCR. Associations with MCI risk and other factors were assessed using regression models.	The shortest and longest TLs were associated with an increased risk of amnesic MCI (aMCI) compared to the middle quintile. TL may be a surrogate marker for etiologic mechanisms influencing cognition.
Scarabino et al., 2019 [32]	OCS	Human n= 176 (n= 76 control; n=38 pre-manifest HD* patients; n=62 manifest HD patients)	Leukocyte telomere length (LTL) was measured using real-time PCR. Statistical analyses examined relationships between LTL and Huntington's disease (HD) development.	LTL was negatively correlated with age. Differences in TL trends were observed between pre-manifest HD patients and controls. LTL may serve as a measure of time to clinical HD onset.
Khan et al., 2015 [29]	Experimental study	C57BL/6J mice n=12 (n=6 for TERC KO (G3 KO)*; n=6 WT)	Using various experimental techniques, telomerase function was manipulated in mice to investigate its effects on microglial cells.	Telomerase-deficient mice exhibited reduced microglial numbers and impaired spatial learning abilities compared to wild-type mice.

(\*RCT: Randomized controlled trial; \*OCS: Observational cross-sectional study; \*PCS: Prospective cohort study; \*OChS: Observational cohort study; \*MCI= Mild cognitive impairment; \*aMCI= amnesic mild cognitive impairment; \*HD= Huntington's disease; \*CAG=the number of trinucleotide repeats of cytosine-adenine-guanine in the HTT gene; \*TERC KO (G3 KO) =TERC knockout mice; \*Wild type)